BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 28576750)

  • 21. Discovery of potent cytotoxic ortho-aryl chalcones as new scaffold targeting tubulin and mitosis with affinity-based fluorescence.
    Zhu C; Zuo Y; Wang R; Liang B; Yue X; Wen G; Shang N; Huang L; Chen Y; Du J; Bu X
    J Med Chem; 2014 Aug; 57(15):6364-82. PubMed ID: 25061803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resveratrol analog (Z)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization.
    Schneider Y; Chabert P; Stutzmann J; Coelho D; Fougerousse A; Gossé F; Launay JF; Brouillard R; Raul F
    Int J Cancer; 2003 Nov; 107(2):189-96. PubMed ID: 12949793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymoquinone inhibits microtubule polymerization by tubulin binding and causes mitotic arrest following apoptosis in A549 cells.
    Acharya BR; Chatterjee A; Ganguli A; Bhattacharya S; Chakrabarti G
    Biochimie; 2014 Feb; 97():78-91. PubMed ID: 24113316
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
    Mahmud F; Deng S; Chen H; Miller DD; Li W
    Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Smart Paclitaxel-Disulfiram Nanococrystals for Efficient MDR Reversal and Enhanced Apoptosis.
    Mohammad IS; He W; Yin L
    Pharm Res; 2018 Feb; 35(4):77. PubMed ID: 29488114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
    Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
    Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
    Zhang Q; Song Y; Cheng X; Xu Z; Matthew OA; Wang J; Sun Z; Zhang X
    Anticancer Res; 2019 Oct; 39(10):5461-5471. PubMed ID: 31570440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of novel 1-indolyl acetate-5-nitroimidazole derivatives of combretastatin A-4 as potential tubulin polymerization inhibitors.
    Yao YF; Wang ZC; Wu SY; Li QF; Yu C; Liang XY; Lv PC; Duan YT; Zhu HL
    Biochem Pharmacol; 2017 Aug; 137():10-28. PubMed ID: 28456516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Resveratrol Based Tubulin Inhibitor Induces Mitotic Arrest and Activates Apoptosis in Cancer Cells.
    Thomas E; Gopalakrishnan V; Hegde M; Kumar S; Karki SS; Raghavan SC; Choudhary B
    Sci Rep; 2016 Oct; 6():34653. PubMed ID: 27748367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
    Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
    Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
    Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glaucarubinone sensitizes KB cells to paclitaxel by inhibiting ABC transporters via ROS-dependent and p53-mediated activation of apoptotic signaling pathways.
    Karthikeyan S; Hoti SL; Nazeer Y; Hegde HV
    Oncotarget; 2016 Jul; 7(27):42353-42373. PubMed ID: 27304668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
    Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
    J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.
    Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP
    J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.